|
|
|
|
|
17.07.26 - 09:42
|
ZKB sorgt für Premiere im Fondsgeschäft (Finews)
|
|
|
Die Zürcher Kantonalbank (ZKB) bringt als erste Anbieterin einen Indexfonds auf den neuen SMI Equal Weight Index der SIX auf den Markt. Das Anlageprodukt soll Schweizer Aktieninvestments breiter diversifizieren und die Dominanz der drei Schwergewichte Nestlé, Novartis und Roche deutlich reduzieren....
|
|
|
|
|
|
|
|
|
15.07.26 - 22:21
|
Moog Inc. to Announce Third Quarter Fiscal 2026 Earnings on July 31, 2026 (Business Wire)
|
|
|
EAST AURORA, N.Y.--(BUSINESS WIRE)--Moog Inc. (NYSE: MOG.A and MOG.B) will release its third quarter fiscal 2026 earnings on Friday, July 31, 2026. In conjunction with this release, Pat Roche, CEO, and Jennifer Walter, CFO, will host a conference call beginning at 10:00 a.m. ET, which will be simultaneously broadcast live online.
Listeners can access the conference call live or in replay mode at http://www.moog.com/investors/events-presentations/. Supplemental slides will be available on the company's website, and the call replay will remain archived for 45 days.
About Moog Inc.
Moog is a worldwide designer, manufacturer, and systems integrator of high-performance precision motion and fluid controls and control systems. Moog's high-performance systems control military and commercial aircraft, satellites, and space vehicles, launch vehicles, defense systems, missiles, automated industrial machinery, marine, and medical equipment. Additional information about the Company can be found at www.moog.com Conta...
|
|
|
|
|
|
|
|
|
15.07.26 - 12:24
|
FDA grants priority review to Roche′s Gazyva/Gazyvaro for pMN (PBR)
|
|
|
The decision is based on results from the Phase III MAJESTY study, which indicated that Gazyva/Gazyvaro achieved a higher rate of complete remission at two years compared to
The post FDA grants priority review to Roche's Gazyva/Gazyvaro for pMN appeared first on Pharmaceutical Business review....
|
|
|
|
|
|
|
15.07.26 - 07:03
|
FDA grants Priority Review to Roche′s Gazyva/Gazyvaro for adults with primary membranous nephropathy (GlobeNewswire EN)
|
|
|
Basel, 15 July 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company's supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The priority review is based on the positive phase III MAJESTY results, which show superiority of Gazyva/Gazyvaro over an immunosuppressive therapy, tacrolimus, in adults with pMN.1 The FDA has already granted Breakthrough Therapy Designation (BTD) to Gazyva/Gazyvaro in pMN and is expected to make a decision on approval by November 2026. This is the second indication in recent months for which the US FDA has granted priority review to Gazyva/Gazyvaro, following idiopathic nephrotic syndrome in May 2026....
|
|
|
14.07.26 - 08:01
|
Roche Unveils Cobas Hepatitis D Virus Test (AFX)
|
|
|
SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it introduced the cobas HDV test for use on the cobas 5800/6800/8800 systems, a diagnostic tool for the detection and qu......
|
|
|
|
|
|
|
13.07.26 - 08:06
|
Sofinnova Partners Appoints David Evans as Partner (Business Wire)
|
|
|
Sofinnova strengthens its growth strategy with a high-caliber London-based Partner:
Physician-scientist combining frontline clinical experience, health financing and policy expertise, and a proven track record in venture capital
Over 20 years in drug development at Bristol Myers Squibb, Eli Lilly, and the Roche Venture Fund as well as in healthcare policy and financing
PARIS--(BUSINESS WIRE)--Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, announced the appointment of David Evans as Partner. A physician-scientist with deep pharma and drug development expertise, Evans joins from the Roche Venture Fund, where he most recently served as Senior Investment Director. His career spans frontline patient care as a doctor in Australia and with Médecins Sans Frontières, health policy and financing at the World Bank, and roles across the pharmaceutical industry in health economics & outcomes research and drug development before...
|
|
|
|
|
10.07.26 - 11:48
|
ABB Robotics collaborates with Roche to bring physical AI to laboratories (Cision)
|
|
|
Zurich, Switzerland, July 8, 2026
ABB Robotics collaborates with Roche to bring physical AI to laboratories
· Agreement lays the foundation for a new era of digitally connected labs enabled by intelligent robotics to provide significant efficiencies in laboratory workflows
· First applications under collaboration will support pathology slide handling and autonomous connectivity in Core Lab intralogistics
· Range of ABB Robotics' technologies deployed, including autonomous mobile manipulation and fixed articulating robots
ABB Robotics has announced a global collaboration...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
